Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy January 21, 2022 by Businesswire [#item_full_content] Related Spread the word
